IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy

Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy
View Sample PDF
Author(s): Carlos Henrique Ferreira Camargo (Hospital Universitário dos Campos Gerais – UEPG, Brazil), Marcus Vinicius Della-Coletta (State University of Amazonas, Brazil), Delson José da Silva (Federal University of Goias, Brazil)and Hélio A. G. Teive (Federal University of Paraná, Brazil)
Copyright: 2019
Pages: 24
Source title: Handbook of Research on Critical Examinations of Neurodegenerative Disorders
Source Author(s)/Editor(s): Md. Sahab Uddin (Southeast University, Bangladesh)and Md. Shah Amran (University of Dhaka, Bangladesh)
DOI: 10.4018/978-1-5225-5282-6.ch013

Purchase

View Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy on the publisher's website for pricing and purchasing information.

Abstract

Alpha-synuclein is a protein that forms a major component of abnormal neuronal aggregates known as Lewy bodies. A particular group of neurodegenerative disorders (NDs) is characterized by the abnormal accumulation of α-synuclein; termed the α-synucleinopathies, this group includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Lysosomal storage diseases have also been linked to α-synuclein toxicity. Several therapeutic targets have been chosen among steps of metabolism of α-synuclein. Reducing α-synuclein synthesis or expression and increasing the clearance can be achieved in many ways. The development of immunotherapeutic approaches targeting α-synuclein has received considerable attention in recent years. The aim of this chapter is to present the α-synucleinopathies, as well as to present the most recent researches about treatment of synucleinopathies based on knowledge of the pathophysiology of α-synuclein pathways.

Related Content

Katie Moraes de Almondes, Gilberto Sousa Alves, Candida Lopes Alves. © 2024. 16 pages.
Jonathan Araujo Queiroz, Gean Sousa, Priscila Lima Rocha, Yonara Costa Magalhões, Allan Kardec Barros Filho. © 2024. 19 pages.
Givago Silva Souza, Brena Karoline Ataíde Furtado, Edilson Brabo Almeida, Bianca Callegari, Maria da Conceição Nascimento Pinheiro. © 2024. 15 pages.
Jonathan Araujo Queiroz, Juliana M. Silva, Yonara Costa Magalhães, Will Ribamar Mendes Almeida, Bárbara Barbosa Correia, José Ricardo Santo de Lima, Edilson Carlos Silva Lima, Marcos Jose Dos Passos Sa, Allan Kardec Barros Filho. © 2024. 14 pages.
Walter Barbalho Soares, Amannda Melo de Oliveira Lima. © 2024. 23 pages.
Gilberto Sousa Alves, Romulo Kunrath Pinto Silva, Marielia Barbosa Freitas Leal, Bianca de Melo Ferro, Leandro de Oliveira Trovão. © 2024. 20 pages.
Felippe Mendonca, Paulo Mattos, Felipe Kenji Sudo. © 2024. 18 pages.
Body Bottom